SGMO250117P1000
- 0.05
- 0.000.00%
Sangamo Therapeutics Newsroom
Sector Update: Health Care Stocks Mixed Premarket Thursday
Sangamo Shares Rally Premarket on License Deal With Astellas
Why Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
Biggest Stock Movers Thursday: MU, MESO, and More
Express News | Sangamo Therapeutics Inc - Eligible for up to $1.3 Billion in Milestone Payments
Express News | Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases
Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 29% Share Price Surge Not Quite Adding Up
Sangamo Surges 24% After Roche Ends Development of Hemophilia A Gene Therapy
Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday
Truist Financial Upgrades Sangamo Therapeutics(SGMO.US) to Buy Rating, Announces Target Price $7
The Analyst Landscape: 6 Takes On Sangamo Therapeutics
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target
Sangamo Therapeutics Analyst Ratings
J.M. Smucker Posts Upbeat Earnings, Joins LexinFintech, Semtech, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
Analyst Forecasts For Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Are Surging Higher
Sangamo Stock Climbs 12% Post-market on FDA Update for ST-503
Sangamo Therapeutics Gets FDA Clearance for Investigational NDA for Pain Treatment
Express News | Sangamo Therapeutics Inc - to Initiate Phase 1/2 Study for St-503 in Mid-2025
Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain
Express News | Sangamo Therapeutics Announces U.S. FDA Clearance of Ind Application for St-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain